238 related articles for article (PubMed ID: 12166042)
1. Tinzaparin sodium: a low-molecular-weight heparin.
Neely JL; Carlson SS; Lenhart SE
Am J Health Syst Pharm; 2002 Aug; 59(15):1426-36. PubMed ID: 12166042
[TBL] [Abstract][Full Text] [Related]
2. Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis.
Hoy SM; Scott LJ; Plosker GL
Drugs; 2010 Jul; 70(10):1319-47. PubMed ID: 20568836
[TBL] [Abstract][Full Text] [Related]
3. Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.
Cheer SM; Dunn CJ; Foster R
Drugs; 2004; 64(13):1479-502. PubMed ID: 15212562
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism.
Wells PS; Anderson DR; Rodger MA; Forgie MA; Florack P; Touchie D; Morrow B; Gray L; O'Rourke K; Wells G; Kovacs J; Kovacs MJ
Arch Intern Med; 2005 Apr; 165(7):733-8. PubMed ID: 15824291
[TBL] [Abstract][Full Text] [Related]
5. Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis.
Dager WE; King JH; Branch JM; Chow SL; Ferrer RE; Pak S; Togioka PY; White RH
Ann Pharmacother; 2005; 39(7-8):1182-7. PubMed ID: 15956232
[TBL] [Abstract][Full Text] [Related]
6. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
[TBL] [Abstract][Full Text] [Related]
7. Tinzaparin in the treatment of venous thromboembolism.
Pineo GF; Hull RD
Expert Opin Pharmacother; 2003 Dec; 4(12):2355-62. PubMed ID: 14640933
[TBL] [Abstract][Full Text] [Related]
8. Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin.
Hyers TM; Spyropoulos AC;
J Thromb Thrombolysis; 2007 Dec; 24(3):225-32. PubMed ID: 17334932
[TBL] [Abstract][Full Text] [Related]
9. Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis.
Chapman TM; Goa KL
Drugs; 2003; 63(21):2357-77. PubMed ID: 14524738
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis.
Barrett JS; Gibiansky E; Hull RD; Planès A; Pentikis H; Hainer JW; Hua TA; Gastonguay M
Int J Clin Pharmacol Ther; 2001 Oct; 39(10):431-46. PubMed ID: 11680668
[TBL] [Abstract][Full Text] [Related]
11. Tinzaparin: considerations for use in clinical practice.
Nutescu EA; Shapiro NL; Feinstein H; Rivers CW
Ann Pharmacother; 2003 Dec; 37(12):1831-40. PubMed ID: 14632588
[TBL] [Abstract][Full Text] [Related]
12. Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders.
Friedel HA; Balfour JA
Drugs; 1994 Oct; 48(4):638-60. PubMed ID: 7528134
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial.
Daskalopoulos ME; Daskalopoulou SS; Tzortzis E; Sfiridis P; Nikolaou A; Dimitroulis D; Kakissis I; Liapis CD
Eur J Vasc Endovasc Surg; 2005 Jun; 29(6):638-50. PubMed ID: 15878544
[TBL] [Abstract][Full Text] [Related]
14. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Hirsh J; Raschke R
Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
[TBL] [Abstract][Full Text] [Related]
15. Tinzaparin.
Wong NN
Heart Dis; 2002; 4(5):331-40. PubMed ID: 12350245
[TBL] [Abstract][Full Text] [Related]
16. Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep® in Renal Insufficiency Study (IRIS).
Leizorovicz A; Siguret V; Mottier D; ; Leizorovicz A; Siguret V; Mottier D; Clonier F; Janas M; Stinson J; Townshend G; Maddalena M
Thromb Res; 2011 Jul; 128(1):27-34. PubMed ID: 21477846
[TBL] [Abstract][Full Text] [Related]
17. Treatment of symptomatic venous thromboembolism: improving outcomes.
Büller HR
Semin Thromb Hemost; 2002 Jun; 28 Suppl 2():41-8. PubMed ID: 12073179
[TBL] [Abstract][Full Text] [Related]
18. Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism.
Wellington K; McClellan K; Jarvis B
Drugs; 2001; 61(8):1185-209. PubMed ID: 11465877
[TBL] [Abstract][Full Text] [Related]
19. Low-molecular-weight heparins in the treatment of deep-vein thrombosis.
Martineau P; Tawil N
Ann Pharmacother; 1998 May; 32(5):588-98, 601. PubMed ID: 9606481
[TBL] [Abstract][Full Text] [Related]
20. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery.
Bara L; Planes A; Samama MM
Br J Haematol; 1999 Feb; 104(2):230-40. PubMed ID: 10050702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
